Moleculin Biotech, Inc. has announced a significant corporate action: a 1-for-20 reverse stock split of its common stock. This decision was made during the company’s annual meeting of stockholders, which took place on October 9, 2026. The reverse split is set to take effect on October 20, 2026, at 12:01 a.m. Eastern Time.
This move is intended to consolidate the number of shares outstanding and potentially increase the stock price, making it more attractive to investors. The company’s common stock will continue to trade under the ticker symbol “MBRX” on The Nasdaq Capital Market, but will be assigned a new CUSIP number.
Company Background
Moleculin Biotech, Inc. is a pharmaceutical company based in Houston, Texas, specializing in developing innovative treatments for cancer and other serious diseases. The company operates under the Standard Industrial Classification (SIC) code 2834, which pertains to Pharmaceutical Preparations. Moleculin is listed on the Nasdaq under the ticker symbol MBRX.
What the Filing Says
According to the filing, the company’s stockholders approved an amendment to the company’s certificate of incorporation to implement the reverse stock split. The filing specifies, “every twenty (20) shares of the Company’s issued and outstanding common stock will automatically be combined into one issued and outstanding share.” As a result, the number of shares outstanding will decrease from approximately 20.91 million to about 1.05 million shares.
Impact
This reverse stock split may impact various stakeholders, including existing shareholders, potential investors, and market analysts. The reduction in the number of shares could lead to a higher trading price per share, which may improve the company’s market perception. Additionally, adjustments will be made to stock options, restricted stock units, and warrants to reflect the new share structure.
What’s Next
The filing does not specify what happens next beyond the effective date of the reverse stock split. However, the company has indicated that it will continue to monitor the effects of this corporate action on its market performance and investor relations.